Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, posted on X:
“Excellent news from FDA ODAC – thanks to AQUILA team and to all the physicians and patients who testified today!
Shared decision-making between patients and MDs will remain key to high-risk smoldering myeloma, and hopefully decision-making will involve daratumumab at some point.”
More posts featuring Rahul Banerjee on OncoDaily.